Ggt1 DTR transgenic mice have a rat gamma-glutamyltransferase 1 (Ggt1) promoter directing expression of a human diphtheria toxin receptor (DTR; heparin-binding epidermal growth factor-like growth factor (HBEGF)) fused to a hemagglutinin (HA) tag and a polyadenylation (polyA) sequence. Transgenic expression is specific to the renal proximal tubule. They are useful for applications requiring diphtheria-mediated ablation of renal proximal tubule cells in hemizygous transgenic mice. Homozygous Ggt1 DTR transgenic mice provide a novel spontaneous kidney tubulointerstitial fibrotic model without diphtheria administration. The homozygous model of spontaneous and progressive renal tubulointerstitial fibrosis characterized by increased collagen deposition, immune cell infiltration, and &alpha;-smooth muscle actin (&alpha;-SMA)-positive myofibroblasts. This disease phenotype is evident as early as age 3 weeks of age and progresses up to age 6 months. Homozygous mice serve as a platform to investigate therapeutic intervention in halting spontaneous disease progression.

Use of MICE by companies or for-profit entities requires a license prior to shipping.

Ggt1 DTR transgenic mice have a rat Ggt1 promoter directing expression of a human diphtheria toxin receptor in the renal proximal tubule. They are useful for applications requiring diphtheria-mediated ablation of renal proximal tubule cells in hemizygous transgenic mice. Homozygous Ggt1 DTR transgenic mice provide a novel spontaneous kidney tubulointerstitial fibrotic model diphtheria administration.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.